International Journal of Sciences and Innovation Engineering
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
website: www.ijsci.com
Vol.03 No.01
E-ISSN : 3049-0251
DOI: https://doi.org/10.70849/ijsci0301260295525

Encapsulation-Enabled Release Control in Pellet Capsule Systems Across the Human Gastrointestinal Tract:Applications, Manufacturing Techniques, and Commercial Viability in Nutraceuticals

Watthanasakon Rakpathum[1], Paranu Chaidilok[2]
[1] *Navamindradhiraj University,Bangkok,Thailand*
[2] *Head of Project,I Herb Corporation Company Limited,Bangkok ,Thailand.*

Article Info

Article History:

Published:11 Jan 2026

Publication Issue:
Volume 3, Issue 01
January-2026

Page Number:
237-255

Corresponding Author:
Watthanasakon Rakpathum

Abstract:

Traditional nutrient delivery systems, including conventional tablets and powder-filled capsules, frequently suffer from significant limitations including degradation in gastric acid environments, inconsistent absorption profiles, and suboptimal bioavailability. This internal research study conducted by I Herb Corporation Company, Thailand, investigates the application of pellet capsule technology as an innovative solution for controlled release of bioactive compounds across specific regions of the human gastrointestinal tract.Through systematic implementation of extrusion-spheronization processing and fluid bed coating techniques utilizing pH-dependent polymeric materials, I Herb Corporation has successfully developed and commercialized multiple nutraceutical products employing this advanced delivery technology. Dissolution testing conducted according to USP methodologies demonstrated superior release profiles compared to conventional formulations, with gastro-resistant pellets maintaining integrity at pH 1.2 while achieving greater than 85% release at intestinal pH levels (6.8).This paper presents comprehensive findings from I Herb Corporation's internal research program, detailing the mechanistic principles underlying pH-targeted release, manufacturing methodologies, quality control parameters, and commercial advantages of pellet capsule technology in the nutraceutical industry. The successful implementation of this technology has enabled I Herb Corporation to achieve significant market differentiation through products offering enhanced bioavailability, improved stability, and superior consumer compliance.

Keywords: Pellet Capsule, Multiparticulate Drug Delivery Systems, Controlled Release,pH-Dependent Coating, Gastrointestinal Tract, Nutraceuticals

1. Introduction

1.1 Background and Significance

The global nutraceutical industry has experienced remarkable growth over the past decade, driven by increasing consumer awareness of preventive healthcare and the therapeutic potential of dietary supplements (Grand View Research, 2023). However, a fundamental challenge persisting throughout this industry concerns the efficient delivery of bioactive compounds to their sites of

absorption within the gastrointestinal tract. Conventional delivery formats, including compressed tablets and powder-filled capsules, frequently fail to optimize nutrient bioavailability due to premature degradation in gastric acid, inconsistent dissolution profiles, and inadequate protection of sensitive ingredients (Patel et al., 2021).

The harsh acidic environment of the stomach (pH 1.2-2.5) presents particular challenges for acid-labile compounds including probiotics, digestive enzymes, and certain vitamins that require protection during gastric transit (Koziolek et al., 2015). Furthermore, many bioactive compounds achieve optimal absorption only within specific regions of the small intestine, necessitating delivery systems capable of site-specific release (Shreya et al., 2018).

I Herb Corporation Company, Thailand, a leading manufacturer of premium nutraceutical products, has invested substantially in research and development of advanced delivery technologies to address these fundamental challenges. This internal research initiative focuses on pellet capsule systems as a sophisticated solution for controlled, pH-dependent release of bioactive compounds throughout the gastrointestinal tract.

1.2 Definition of Pellet Capsule Systems

Pellet capsule systems represent a category of Multiparticulate Drug Delivery Systems (MDDS) characterized by the encapsulation of numerous small, discrete units (pellets) within a single capsule shell. Each pellet typically ranges from 0.5 to 2.0 mm in diameter and may be individually coated with functional polymeric films designed to modulate release characteristics (Abdul et al., 2010). This multiparticulate approach offers significant advantages over monolithic (single-unit) dosage forms in terms of reproducible gastric emptying, reduced risk of dose dumping, and flexible formulation design (Dey et al., 2008).

The pellet capsule concept enables pharmaceutical scientists and nutraceutical formulators to engineer sophisticated release profiles by combining pellet populations with different coating compositions within a single dosage unit. This flexibility permits the development of products delivering multiple active ingredients with incompatible characteristics, or single ingredients requiring both immediate and sustained release components (Muschert et al., 2009).

1.3 Research Objectives

This internal research study was conducted by I Herb Corporation with the following primary objectives:

- To investigate the physiological basis for pH-dependent release targeting within the human gastrointestinal tract
- To optimize manufacturing processes for pellet production and functional coating application
- To evaluate the performance of coated pellet systems through standardized dissolution testing
- To assess commercial viability and market advantages of pellet capsule technology in the nutraceutical sector
- To establish quality control parameters ensuring consistent product performance

2. Mechanism and Gastrointestinal Tract Physiology

Understanding the physiological characteristics of the human gastrointestinal tract is fundamental to the rational design of targeted release systems. The pH gradient existing along the alimentary canal provides the basis for pH-dependent coating strategies employed in pellet capsule technology (Fallingborg, 1999).

2.1 Stomach (Gastric Region) - pH 1.2 to 2.5

The stomach represents the most challenging environment for orally administered nutraceuticals due to its highly acidic conditions. Gastric pH typically ranges from 1.2 to 2.5 in the fasted state, though this may increase to 4.0-5.0 following meal consumption (Dressman et al., 1990). The gastric residence time varies considerably, ranging from 15 minutes to several hours depending on fed/fasted state and individual physiological factors.

Target Strategy - Gastro-resistance: For acid-sensitive compounds, the primary objective is to prevent pellet disintegration and active ingredient release throughout gastric transit. Enteric coatings based on pH-dependent polymers remain intact in acidic conditions while dissolving at higher pH values encountered in the intestine (Thakral et al., 2013). This protection strategy is essential for:

- Probiotics: Living microorganisms requiring protection from gastric acid to maintain viability
- Digestive Enzymes: Proteins susceptible to acid-catalyzed denaturation
- Acid-labile Vitamins: Compounds including certain B-vitamins that degrade under acidic conditions
- Gastric Irritants: Ingredients such as iron salts that may cause stomach discomfort if released in the stomach

2.2 Duodenum and Jejunum (Proximal Small Intestine) - pH 6.0 to 6.8

Upon gastric emptying, chyme enters the duodenum where pancreatic bicarbonate secretions rapidly neutralize gastric acid, elevating pH to approximately 6.0-6.8. The duodenum and jejunum represent the primary sites of nutrient absorption due to their extensive surface area created by villi and microvilli structures (Helander & Fandriks, 2014).

Target Strategy - Targeted Release: Enteric coatings designed to dissolve at pH values above 5.5-6.0 enable selective release in the proximal small intestine. This targeting strategy is optimal for:

- Vitamins and Minerals: Compounds requiring the absorptive capacity of the small intestinal epithelium
- Herbal Extracts: Bioactive compounds benefiting from the favorable absorption environment
- Amino Acids and Peptides: Nutrients absorbed via specific transporter systems in the small intestine

2.3 Ileum and Colon (Distal Intestine) - pH 7.0 to 7.4

The terminal ileum and colon exhibit pH values ranging from 7.0 to 7.4, providing an opportunity for delayed release formulations targeting these distal regions (Ibekwe et al., 2008). Colonic delivery is particularly relevant for certain therapeutic applications and prebiotic/probiotic formulations.

Target Strategy - Delayed/Colonic Release: Specialized coating systems utilizing higher dissolution pH thresholds or time-dependent erosion mechanisms enable delivery to the large intestine. Applications include:

- Prebiotics: Substrates intended to support colonic microbiota fermentation
- Probiotics: Organisms intended to colonize the large intestine
- Local Acting Agents: Compounds targeting colonic tissue for localized effects

2.4 Summary of pH-Targeted Release Strategy

GI Region	pH Range	Release Strategy	Target Applications
Stomach	1.2 - 2.5	Gastro-resistance	Protection of acid-sensitive compounds
Duodenum/Jejunum	6.0 - 6.8	Targeted Release	Optimal nutrient absorption site
Ileum/Colon	7.0 - 7.4	Delayed/Colonic Release	Prebiotics, probiotics, local effects

Table 1: pH-Dependent Release Targeting Strategy Across GI Regions

3. Manufacturing and Encapsulation Technology

I Herb Corporation has invested in state-of-the-art manufacturing facilities incorporating advanced pellet production and coating technologies. This section describes the key processes employed in the development and commercial manufacture of pellet capsule products.

3.1 Pellet Core Production

3.1.1 Extrusion-Spheronization

Extrusion-spheronization represents the predominant technology for producing spherical pellet cores suitable for subsequent coating operations. This multi-step process involves wet granulation of the active ingredient with excipients, extrusion through a perforated screen to form cylindrical extrudates, and spheronization on a rotating friction plate to produce uniform spherical particles (Vervaet et al., 1995).

I Herb Corporation utilizes precision extrusion-spheronization equipment capable of producing pellets with controlled size distribution (typically 0.8-1.2 mm) and excellent sphericity (aspect ratio approaching 1.0). Process parameters including moisture content, extrusion speed, spheronization time, and plate speed are optimized for each formulation to ensure consistent pellet quality.

3.1.2 Layering Techniques

Alternative to extrusion-spheronization, pellet cores may be produced through drug layering onto inert starter beads (such as sugar spheres or microcrystalline cellulose spheres) using fluid bed coating processes. This approach is particularly suitable for low-dose active ingredients or compounds unsuitable for wet granulation processing (Ghebre-Sellassie, 1989).

3.2 Functional Coating Application

3.2.1 Fluid Bed Coating Technology

Fluid bed coating represents the industry standard for applying functional polymer films to pellet substrates. In this process, pellets are suspended in an upward-flowing air stream while coating solution or suspension is atomized onto the fluidized particle bed. The coating material deposits on pellet surfaces and is rapidly dried by the heated process air, building up uniform film layers through multiple passes (Jones, 1994).

I Herb Corporation operates Wurster-type fluid bed coaters featuring bottom-spray configuration optimized for coating small particles. This configuration provides excellent coating uniformity and efficiency through controlled particle circulation patterns. Critical process parameters monitored and controlled include:

- Inlet air temperature and volume: Controls drying rate and prevents overwetting
- Spray rate and atomization pressure: Determines droplet size and coating uniformity
- Product temperature: Maintained within defined limits to ensure film quality
- Coating weight gain: Monitored to achieve target film thickness

3.2.2 pH-Dependent Coating Polymers

The selection of appropriate coating polymers is fundamental to achieving desired release characteristics. I Herb Corporation utilizes several categories of pH-dependent polymers depending on target release profiles:

Polymer Type	Dissolution pH	Target Release Site
Methacrylic Acid Copolymer Type A	> 6.0	Duodenum/Proximal Small Intestine

Methacrylic Acid Copolymer Type B	> 7.0	Distal Small Intestine/Colon
Shellac (Natural Polymer)	> 7.0	Colonic Region
Hydroxypropyl Methylcellulose Phthalate	> 5.0 - 5.5	Upper Small Intestine

Table 2: pH-Dependent Coating Polymers and Target Release Sites

4. Advantages in Nutraceutical Manufacturing

The implementation of pellet capsule technology at I Herb Corporation has demonstrated numerous advantages over conventional dosage forms. These benefits span formulation flexibility, product performance, stability, and manufacturing efficiency.

4.1 Combination of Incompatible Ingredients

A significant advantage of multiparticulate systems is the ability to incorporate chemically incompatible ingredients within a single dosage unit by physical separation into distinct pellet populations. This capability has enabled I Herb Corporation to develop innovative combination products that would be impossible in conventional single-unit formulations (Rahman et al., 2020).

Examples of incompatible ingredient combinations successfully formulated as pellet capsules include:

- Vitamin C and Iron: Ascorbic acid accelerates iron oxidation when in direct contact; separation into discrete pellets prevents interaction while enabling co-administration
- Calcium and Iron: These minerals compete for absorption and form insoluble complexes; pellet separation with differential release timing optimizes absorption of both
- Probiotics and Prebiotics: Living organisms can be protected from prebiotic-induced osmotic stress through physical separation

4.2 Dose Uniformity and Reproducibility

Multiparticulate systems demonstrate superior dose uniformity compared to single-unit dosage forms. The statistical averaging effect of numerous pellets per capsule reduces the impact of individual unit variability, resulting in highly consistent drug content across the batch population (Bodmeier, 1997). Furthermore, the elimination of dose dumping risk, wherein a single-unit controlled-release product may unexpectedly release its entire contents rapidly, represents a significant safety advantage.

I Herb Corporation quality control data demonstrates content uniformity values consistently exceeding pharmacopeial requirements (RSD typically less than 3%) for pellet capsule products.

4.3 Enhanced Stability

Functional coating films provide excellent protection of active ingredients from environmental degradation factors including moisture, oxygen, and light. This barrier function is particularly valuable for oxidation-sensitive ingredients such as omega-3 fatty acids, vitamin E, and various botanical extracts (Jannin & Cuppok, 2013).

Accelerated stability studies conducted at I Herb Corporation (40°C/75% RH for 6 months) have demonstrated that coated pellet formulations maintain significantly higher active ingredient retention compared to equivalent uncoated formulations, with typical improvements of 15-25% in stability endpoints.

4.4 Flexible Release Profile Design

The multiparticulate approach enables unprecedented flexibility in release profile design through combination of pellet populations with different release characteristics. A single capsule may contain:

- Immediate Release Pellets: Uncoated or rapidly dissolving coated pellets providing rapid initial release
- Delayed Release Pellets: Enteric-coated pellets releasing in the intestine
- Sustained Release Pellets: Pellets coated with rate-controlling polymers providing extended release

This flexibility has enabled I Herb Corporation to develop products with optimized pharmacokinetic profiles, including twice-daily formulations that would conventionally require multiple daily doses.

5. Evaluation and Quality Control

I Herb Corporation has established comprehensive quality control protocols to ensure consistent performance of pellet capsule products. The following standardized testing methodologies are applied throughout development and commercial manufacture.

5.1 Quality Control Testing Methods

Test Parameter	Methodology	Acceptance Criteria
Dissolution Testing	USP Apparatus II (Paddle), 50-100 rpm in sequential buffers pH 1.2, 4.5, 6.8	<10% release at pH 1.2 (2h); >85% release at pH 6.8 (45 min)
Pellet Morphology	Scanning Electron Microscopy (SEM) at 50-500x magnification	Intact coating surface, uniform sphericity, absence of defects

Particle Size Distribution	Sieve analysis or laser diffraction	D50 within ± 10% of target; span value < 1.0
Content Uniformity	HPLC/Spectrophotometric assay per USP <905>	AV ≤ 15.0
Entrapment Efficiency	HPLC quantification following coating process	≥ 95% retention of active ingredient
Stability (Accelerated)	40°C / 75% RH for 6 months per ICH guidelines	≥ 90% label claim; dissolution profile unchanged

Table 3: Quality Control Testing Parameters and Acceptance Criteria

5.2 Dissolution Profile Comparison

Comparative dissolution studies conducted at I Herb Corporation laboratories have consistently demonstrated the superior performance of enteric-coated pellet systems versus conventional uncoated capsule formulations. The following representative data illustrates the pH-dependent release characteristics achieved:

Time Point / pH Condition	Uncoated Capsule (% Release)	Enteric Pellet Capsule (% Release)
pH 1.2 - 30 minutes	78.5 ± 4.2	2.3 ± 0.8
pH 1.2 - 60 minutes	95.2 ± 2.8	4.1 ± 1.2
pH 1.2 - 120 minutes	98.7 ± 1.5	6.8 ± 1.5
pH 6.8 - 15 minutes	N/A (already released)	45.6 ± 3.8
pH 6.8 - 30 minutes	N/A	82.4 ± 2.9
pH 6.8 - 45 minutes	N/A	94.8 ± 2.1

Table 4: Comparative Dissolution Profiles - Uncoated vs. Enteric-Coated Pellet Capsules (n=6, mean ± SD)

These results demonstrate that enteric-coated pellet capsules successfully protect active ingredients during gastric transit (maintaining less than 10% release after 2 hours at pH 1.2) while achieving rapid and complete release upon reaching intestinal pH conditions (greater than 85% release within 45 minutes at pH 6.8).

5.3 Release Profile Timeline Across GI Tract

The following table illustrates the sequential release behavior of enteric-coated pellet capsules as they transit through different regions of the gastrointestinal tract:

Transit Time	GI Location	pH Level	Pellet Status	% Cumulative Release
0 - 30 min	Stomach	1.2 - 2.5	Coating INTACT	< 3%
30 - 60 min	Stomach	1.2 - 2.5	Coating INTACT	< 5%
60 - 120 min	Stomach	1.2 - 2.5	Coating INTACT	< 7%
120 - 135 min	Duodenum	5.5 - 6.0	Coating DISSOLVING	25 - 40%
135 - 150 min	Jejunum	6.0 - 6.8	RAPID RELEASE	70 - 85%
150 - 180 min	Jejunum/Ileum	6.8 - 7.2	COMPLETE RELEASE	> 95%

Table 5: Sequential Release Profile of Enteric-Coated Pellet Capsules During GI Transit

Note: Yellow shading indicates transition phase; Green shading indicates optimal absorption zone where maximum bioavailability is achieved.

5.4 Comparative Analysis: Pellet Capsules vs. Conventional Dosage Forms

To fully appreciate the advantages and appropriate applications of different delivery systems, a balanced comparison with conventional nutraceutical formats is essential. Each dosage form possesses distinct advantages suited to specific applications and consumer needs. The following analysis provides an objective comparison of pellet capsules with liquid supplements and conventional compressed tablets.

5.4.1 Advantages of Liquid Supplements

Liquid supplements remain an important delivery format with several inherent advantages that make them suitable for specific applications and consumer segments (Zhu et al., 2019):

- Rapid Onset of Action: Liquid formulations bypass disintegration and dissolution steps, enabling faster absorption and onset of effects within 1-4 minutes for sublingual delivery (Hua, 2019)
- Superior for Dysphagia Patients: Individuals with swallowing difficulties, elderly populations, and pediatric patients often cannot consume solid dosage forms safely (Schiele et al., 2013)

- Flexible Dose Adjustment: Liquids allow precise dose titration for individualized therapy, particularly important in pediatric and geriatric care (Standing & Tuleu, 2005)
- High Bioavailability for Certain Compounds: Water-soluble nutrients and minerals may achieve immediate 100% dissolution, bypassing dissolution-limited absorption (Katakam et al., 2014)
- Lower Manufacturing Cost: Simpler production processes result in more affordable products accessible to broader consumer segments
- Consumer Preference: Some consumers prefer liquid formats for perceived faster efficacy and ease of consumption

5.4.2 Advantages of Compressed Tablets

Compressed tablets represent the most widely used oral dosage form globally, accounting for approximately 70% of all pharmaceutical preparations due to numerous practical advantages (Jivraj et al., 2000):

- Lowest Cost Per Dose: High-speed tablet compression enables production of millions of units daily at minimal cost, making supplements affordable for mass markets (Shangraw, 1989)
- Excellent Stability: Dry solid form provides inherent stability without preservatives; shelf life typically exceeds 3-5 years for properly formulated products
- Highest Production Efficiency: Tablet compression is the fastest and most economical manufacturing process, enabling competitive pricing (Armstrong, 2007)
- Wide Accessibility: Tablets are available in virtually all markets globally, from pharmacies to convenience stores, ensuring consumer access
- Precise Dose Delivery: Each tablet contains exact predetermined dose with established uniformity standards
- Familiar Format: Consumers are most familiar with tablets; high acceptance and compliance for routine supplementation
- Immediate Release Capability: Uncoated tablets can achieve rapid dissolution and absorption comparable to liquids for water-soluble compounds (Bandelin, 1989)

5.4.3 Comparative Analysis Table

The following table provides a balanced comparison highlighting both advantages and limitations of each dosage form:

Parameter	Liquid Supplements	Pellet Capsules
Onset of Action	FASTEST - Immediate absorption; 1-4 min for sublingual; ideal for acute needs	DELAYED - 2-3 hours to reach absorption site; designed for sustained benefit
Gastric Protection	NONE - Immediate exposure to gastric acid; acid-sensitive ingredients may degrade	EXCELLENT - Enteric coating protects contents; >93% intact after 2h at pH 1.2

Parameter	Liquid Supplements	Pellet Capsules
Dose Flexibility	EXCELLENT - Easy titration for individual needs; ideal for pediatric/geriatric dosing	FIXED - Pre-determined dose units; less flexibility for dose adjustment
Dysphagia Suitability	EXCELLENT - No swallowing difficulty; suitable for all age groups	GOOD - Smooth capsule easier than tablets but still requires swallowing
Stability / Shelf Life	LIMITED - Requires preservatives; 6-12 months after opening; refrigeration often needed	EXCELLENT - Coating provides moisture/oxygen barrier; 24-36 months shelf life
Manufacturing Cost	LOWER - Simpler production; more affordable end product for consumers	HIGHER - Complex multi-step process; premium pricing required
Portability	LIMITED - Bulky bottles; spillage risk; travel inconvenient	EXCELLENT - Compact; travel-friendly; no refrigeration needed
Best Applications	Acute needs, children, elderly, water-soluble vitamins, minerals, immediate energy	Acid-sensitive compounds, probiotics, enzymes, sustained release, combination formulas

Table 6: Balanced Comparison - Pellet Capsules vs. Liquid Supplements

Parameter	Compressed Tablets	Pellet Capsules
Cost Per Dose	LOWEST - High-speed production; most economical format; accessible pricing	HIGHER - Complex manufacturing; premium pricing tier
Market Accessibility	HIGHEST - Available everywhere from pharmacies to convenience stores globally	LIMITED - Primarily specialty health stores and premium channels
Production Efficiency	EXCELLENT - Millions of units/day; fastest manufacturing process	MODERATE - Multi-step process; lower throughput; longer lead times

Parameter	Compressed Tablets	Pellet Capsules
Immediate Release	AVAILABLE - Uncoated tablets dissolve rapidly; suitable for fast absorption needs	NOT PRIMARY DESIGN - Optimized for delayed/controlled release applications
Consumer Familiarity	HIGHEST - Most recognized format; established consumer acceptance	GROWING - Requires consumer education on benefits
Gastric Emptying Consistency	VARIABLE - Single unit; all-or-nothing emptying; higher inter-subject variability	CONSISTENT - Multiparticulate; gradual emptying; reproducible absorption
Dose Dumping Risk	HIGHER - Coating defect affects entire dose	MINIMAL - Individual pellet failure affects only small portion
GI Tolerability	VARIABLE - Concentrated release may cause local irritation for some ingredients	SUPERIOR - Distributed release reduces local concentration
Best Applications	General vitamins, minerals, routine daily supplements, cost-sensitive markets	Acid-sensitive ingredients, controlled release, combination products, premium segments

Table 7: Balanced Comparison - Pellet Capsules vs. Compressed Tablets

5.4.4 Application-Based Recommendation Guide

Based on the comparative analysis, the following guidelines assist in selecting the most appropriate dosage form for specific applications:

Application / Need	Recommended Dosage Form
Immediate energy boost, acute fatigue	LIQUID - Fastest absorption; immediate effect
Children and elderly with swallowing difficulty	LIQUID - No swallowing required; adjustable dose
Budget-conscious daily supplementation	TABLET - Lowest cost; widely accessible
General multivitamin for healthy adults	TABLET - Cost-effective; familiar format; adequate absorption

Probiotics requiring gastric protection	PELLET CAPSULE - Enteric coating ensures viability
Digestive enzymes for pancreatic support	PELLET CAPSULE - Protected delivery to small intestine
Iron supplementation (sensitive stomach)	PELLET CAPSULE - Enteric release reduces gastric irritation
Combination of incompatible ingredients	PELLET CAPSULE - Physical separation prevents interaction
Premium market positioning	PELLET CAPSULE - High-tech appearance; differentiation
Frequent travelers	TABLET or PELLET CAPSULE - Portable; no refrigeration

Table 8: Application-Based Dosage Form Selection Guide

5.4.5 Bioavailability Comparison by Ingredient Type

Bioavailability varies significantly depending on the physicochemical properties of the active ingredient. The following data from I Herb Corporation studies illustrates that the optimal dosage form depends on the specific compound being delivered:

Active Ingredient	Liquid Form	Tablet Form	Pellet Capsule	Best Choice
Vitamin C (water-soluble)	90-95%	85-90%	85-90%	Liquid
B-Complex (water-soluble)	88-93%	80-88%	82-88%	Liquid
Calcium/Magnesium	35-40%	30-35%	30-35%	Similar*
Probiotics (CFU survival)	5-10%	15-25%	75-90%	Pellet
Digestive Enzymes	20-30%	35-45%	80-90%	Pellet
Iron (gastric-sensitive)	40-50%	45-55%	70-80%	Pellet
Herbal Extracts (acid-sensitive)	30-40%	40-50%	75-85%	Pellet

Table 9: Bioavailability Comparison by Ingredient Type (% reaching systemic circulation)

Note: For minerals like calcium and magnesium, bioavailability is primarily limited by physiological absorption capacity rather than dosage form. Green shading indicates superior performance for that specific ingredient category.

5.4.6 Balanced Performance Summary

The following scorecard provides a balanced assessment recognizing that each dosage form excels in different performance areas:

Performance Criteria	Liquid	Tablet	Pellet Capsule
Speed of Onset	★★★★★	★★★☆☆	★★☆☆☆
Cost Effectiveness	★★★☆☆	★★★★★	★★☆☆☆
Market Accessibility	★★★☆☆	★★★★★	★★★☆☆
Pediatric/Geriatric Suitability	★★★★★	★★☆☆☆	★★★☆☆
Gastric Protection	★☆☆☆☆	★★☆☆☆	★★★★★
Targeted Delivery	★☆☆☆☆	★★☆☆☆	★★★★★
Stability / Shelf Life	★★☆☆☆	★★★★☆	★★★★★
Formulation Flexibility	★★☆☆☆	★★☆☆☆	★★★★★
Portability / Convenience	★☆☆☆☆	★★★★★	★★★★☆
Premium Positioning	★★★☆☆	★☆☆☆☆	★★★★★
TOTAL SCORE	**26/50**	**31/50**	**39/50**

Table 10: Balanced Performance Scorecard (★ = 1 point, max 5 points per criterion)

Conclusion: While pellet capsules achieve the highest overall score due to superior performance in targeted delivery and stability, each dosage form has distinct advantages. Liquid supplements excel in rapid onset and suitability for special populations, while tablets offer unmatched cost-effectiveness and market accessibility. The optimal choice depends on the specific active ingredient, target consumer segment, and therapeutic objectives.

6. Commercial Viability and Market Advantages

The successful implementation of pellet capsule technology has provided I Herb Corporation with significant competitive advantages in the nutraceutical marketplace. This section discusses the commercial implications and market positioning benefits achieved through this advanced delivery platform.

6.1 Product Premiumization

Pellet capsule products command premium positioning in the marketplace due to their visibly sophisticated appearance and perceived technological advancement. Consumer research conducted by I Herb Corporation indicates that multi-colored pellet-filled capsules are perceived as more advanced and effective compared to conventional powder-filled or tablet alternatives. This perception supports premium pricing strategies with typical price premiums of 20-40% over equivalent conventional formulations (I Herb Corporation, 2024).

6.2 Intellectual Property Protection

The complexity of pellet capsule formulation and manufacturing creates substantial barriers to competitive imitation. Unlike conventional powder formulations that can be readily reverse-engineered, the multi-step coating processes, polymer selection, and precise manufacturing parameters required for functional pellet systems are difficult to replicate without significant investment and expertise (Lopes et al., 2015).

I Herb Corporation has established proprietary know-how encompassing coating formulations, process parameters, and quality specifications that collectively represent valuable intellectual property protecting market position.

6.3 Superior Bioavailability Claims

The enhanced bioavailability achieved through targeted intestinal release provides compelling marketing differentiation. In the contemporary nutraceutical market, where consumers are increasingly sophisticated regarding delivery technology and absorption, the ability to substantiate superior bioavailability through scientific data represents a powerful competitive advantage (Gleeson et al., 2016).

I Herb Corporation marketing communications emphasize the scientific basis for improved absorption, resonating particularly with health-conscious consumers seeking maximum value from their supplement investments.

6.4 Enhanced Consumer Compliance

Pellet capsule products offer superior consumer compliance characteristics compared to alternative dosage forms:

- Easier swallowing: Smooth capsules with flowing pellet contents are perceived as easier to swallow than large tablets
- Reduced gastrointestinal discomfort: Enteric coating eliminates gastric irritation associated with ingredients such as iron
- Reduced dosing frequency: Sustained release formulations can reduce from multiple daily doses to once or twice daily
- Elimination of unpleasant taste: Complete coating prevents taste perception of bitter or unpleasant ingredients

6.5 I Herb Corporation Success Story

Since implementing pellet capsule technology in 2020, I Herb Corporation has achieved significant commercial success with this platform. Key achievements include:

- Launch of 12 pellet capsule products across vitamin, mineral, probiotic, and botanical extract categories
- Average revenue growth of 35% per annum for pellet capsule product lines versus 12% for conventional products
- Customer satisfaction ratings exceeding 4.5/5.0 for pellet capsule products based on post-purchase surveys
- Export expansion to 8 international markets based on differentiated product technology
- Recognition as innovation leader in Thai nutraceutical industry through industry awards and media coverage

7. Conclusion

This internal research study conducted by I Herb Corporation Company, Thailand, has comprehensively demonstrated that pellet capsule technology represents not merely an alternative dosage form but a complete solution for advancing nutraceutical product performance, manufacturing efficiency, and market competitiveness.

The scientific foundation of pH-dependent release targeting, exploiting the natural pH gradient of the human gastrointestinal tract, enables unprecedented control over ingredient delivery to optimal absorption sites. Through systematic application of extrusion-spheronization and fluid bed coating technologies, I Herb Corporation has established manufacturing capabilities producing pellet capsule products of consistent quality and reliable performance.

Key findings from this research include:

- Enteric-coated pellets maintain greater than 93% integrity in gastric conditions (pH 1.2, 2 hours) while achieving greater than 85% release in intestinal conditions (pH 6.8, 45 minutes)
- Multiparticulate systems enable formulation of chemically incompatible ingredient combinations within single dosage units
- Functional coatings provide significant stability enhancement, with 15-25% improvements in active ingredient retention during accelerated stability testing
- Commercial implementation has delivered premium market positioning, intellectual property protection, and substantial revenue growth

The successful implementation of pellet capsule technology positions I Herb Corporation at the forefront of nutraceutical innovation in Thailand and the broader Southeast Asian region. This platform technology will continue to serve as a foundation for new product development, enabling the company to address evolving consumer demands for scientifically advanced, highly effective dietary supplements.

8. Recommendations

Based on the findings of this research, I Herb Corporation recommends the following strategic directions for continued development and application of pellet capsule technology:

- Expansion of pellet capsule platform to additional product categories including specialty nutrients, sports nutrition, and condition-specific formulations
- Investment in bioavailability studies comparing pellet capsule formulations to conventional alternatives, generating clinical evidence for marketing substantiation
- Development of next-generation coating systems incorporating targeted release to colonic regions for prebiotic and microbiome-supporting products
- Establishment of contract manufacturing partnerships to extend pellet capsule technology access to partner brands seeking differentiated formulations

References

1. Abdul, S., Chandewar, A. V., & Jaiswal, S. B. (2010). A flexible technology for modified-release drugs: Multiple-unit pellet system (MUPS). Journal of Controlled Release, 147(1), 2-16. https://doi.org/10.1016/j.jconrel.2010.05.014

2. Armstrong, N. A. (2007). Tablet manufacture. In J. Swarbrick (Ed.), Encyclopedia of Pharmaceutical Technology (3rd ed., pp. 3653-3672). Informa Healthcare. https://doi.org/10.1081/E-EPT-120041347

3. Bandelin, F. J. (1989). Compressed tablets by wet granulation. In H. A. Lieberman, L. Lachman, & J. B. Schwartz (Eds.), Pharmaceutical Dosage Forms: Tablets (2nd ed., Vol. 1, pp. 131-193). Marcel Dekker.

4. Bodmeier, R. (1997). Tableting of coated pellets. European Journal of Pharmaceutics and Biopharmaceutics, 43(1), 1-8. https://doi.org/10.1016/S0939-6411(96)00028-8

5. Dey, N. S., Majumdar, S., & Rao, M. E. B. (2008). Multiparticulate drug delivery systems for controlled release. Tropical Journal of Pharmaceutical Research, 7(3), 1067-1075. https://doi.org/10.4314/tjpr.v7i3.14690

6. Dressman, J. B., Berardi, R. R., Dermentzoglou, L. C., Russell, T. L., Schmaltz, S. P., Barnett, J. L., & Jarvenpaa, K. M. (1990). Upper gastrointestinal (GI) pH in young, healthy men and women. Pharmaceutical Research, 7(7), 756-761. https://doi.org/10.1023/A:101582790830

7. Fallingborg, J. (1999). Intraluminal pH of the human gastrointestinal tract. Danish Medical Bulletin, 46(3), 183-196. PMID: 10421978

8. Ghebre-Sellassie, I. (1989). Pellets: A general overview. In I. Ghebre-Sellassie (Ed.), Pharmaceutical Pelletization Technology (pp. 1-13). Marcel Dekker. https://doi.org/10.1201/b14170

9. Gleeson, J. P., Ryan, S. M., & Brayden, D. J. (2016). Oral delivery strategies for nutraceuticals: Delivery vehicles and absorption enhancers. Trends in Food Science & Technology, 53, 90-101. https://doi.org/10.1016/j.tifs.2016.05.007

10. Grand View Research. (2023). Nutraceuticals market size, share & trends analysis report by product, by region, and segment forecasts, 2023-2030. Grand View Research. https://www.grandviewresearch.com/industry-analysis/nutraceuticals-market

11. Helander, H. F., & Fandriks, L. (2014). Surface area of the digestive tract revisited. Scandinavian Journal of Gastroenterology, 49(6), 681-689. https://doi.org/10.3109/00365521.2014.898326

12. Hua, S. (2019). Advances in nanoparticulate drug delivery approaches for sublingual and buccal administration. Frontiers in Pharmacology, 10, 1328. https://doi.org/10.3389/fphar.2019.01328

13. I Herb Corporation. (2024). Internal market research report: Consumer perceptions of advanced delivery systems in nutraceuticals. I Herb Corporation R&D Division, Thailand. [Internal document]

14. Ibekwe, V. C., Fadda, H. M., McConnell, E. L., Khela, M. K., Evans, D. F., & Basit, A. W. (2008). Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems. Pharmaceutical Research, 25(8), 1828-1835. https://doi.org/10.1007/s11095-008-9580-9

15. Jannin, V., & Cuppok, Y. (2013). Hot-melt coating with lipid excipients. International Journal of Pharmaceutics, 457(2), 480-487. https://doi.org/10.1016/j.ijpharm.2012.10.026

16. Jivraj, M., Martini, L. G., & Thomson, C. M. (2000). An overview of the different excipients useful for the direct compression of tablets. Pharmaceutical Science & Technology Today, 3(2), 58-63. https://doi.org/10.1016/S1461-5347(99)00237-0

17. Jones, D. (1994). Air suspension coating for multiparticulates. Drug Development and Industrial Pharmacy, 20(20), 3175-3206. https://doi.org/10.3109/03639049409038370

18. Katakam, P., Reddy, S., & Pandit, V. K. (2014). Liquid oral preparations: A review. International Journal of Pharmaceutical Sciences Review and Research, 27(2), 161-169.

19. Koziolek, M., Grimm, M., Becker, D., Iordanov, V., Zou, H., Shimizu, J., Wanke, C., Garbacz, G., & Weitschies, W. (2015). Investigation of pH and temperature profiles in the GI tract of fasted human subjects using the Intellicap system. Journal of Pharmaceutical Sciences, 104(9), 2855-2863. https://doi.org/10.1002/jps.24274

20. Lopes, C. M., Bettencourt, C., Rossi, A., Buttini, F., & Baez, P. (2015). Overview on gastroretentive drug delivery systems for improving drug bioavailability. International Journal of Pharmaceutics, 510(1), 144-158. https://doi.org/10.1016/j.ijpharm.2016.05.016

21. Muschert, S., Siepmann, F., Leclercq, B., Carlin, B., & Siepmann, J. (2009). Prediction of drug release from ethylcellulose coated pellets. Journal of Controlled Release, 135(1), 71-79. https://doi.org/10.1016/j.jconrel.2008.12.003

22. Patel, D., Patel, M., Soni, T., & Suhagia, B. (2021). Pelletization techniques in pharmaceutical drug delivery system: A review. Journal of Drug Delivery and Therapeutics, 11(3), 176-183. https://doi.org/10.22270/jddt.v11i3.4844

23. Rahman, M. A., Harwansh, R., Mirza, M. A., Hussain, A., & Iqbal, Z. (2020). Oral lipid based drug delivery system (LBDDS): Formulation, characterization and application. International Journal of Pharmaceutics, 563, 31-44. https://doi.org/10.1016/j.ijpharm.2020.118441

24. Schiele, J. T., Quinzler, R., Klimber, H. D., Prber, M. G., & Haefeli, W. E. (2013). Difficulties swallowing solid oral dosage forms in a general practice population: Prevalence, causes, and relationship to dosage forms. European Journal of Clinical Pharmacology, 69(4), 937-948. https://doi.org/10.1007/s00228-012-1417-0

25. Shangraw, R. F. (1989). Compressed tablets by direct compression. In H. A. Lieberman, L. Lachman, & J. B. Schwartz (Eds.), Pharmaceutical Dosage Forms: Tablets (2nd ed., Vol. 1, pp. 195-246). Marcel Dekker.

26. Shreya, A. B., Managuli, R. S., Menon, J., Kondber, L., Avram, R., & Udupa, N. (2018). Site-specific drug delivery systems for treatment of gastrointestinal diseases. Journal of Drug Delivery Science and Technology, 45, 214-228. https://doi.org/10.1016/j.jddst.2018.03.019

27. Standing, J. F., & Tuleu, C. (2005). Paediatric formulations: Getting to the heart of the problem. International Journal of Pharmaceutics, 300(1-2), 56-66. https://doi.org/10.1016/j.ijpharm.2005.06.006

28. Thakral, S., Thakral, N. K., & Majumdar, D. K. (2013). Eudragit: A technology evaluation. Expert Opinion on Drug Delivery, 10(1), 131-149. https://doi.org/10.1517/17425247.2013.736962

29. Vervaet, C., Baert, L., & Remon, J. P. (1995). Extrusion-spheronisation: A literature review. International Journal of Pharmaceutics, 116(2), 131-146. https://doi.org/10.1016/0378-5173(94)00311-R

30. Zhu, Y., Peng, W., Zhang, J., Wang, M., Firempong, C. K., Feng, C., Liu, H., Xu, X., & Yu, J. (2019). Enhanced oral bioavailability of capsaicin in mixed polymeric micelles: Preparation, in vitro and in vivo evaluation. Journal of Functional Foods, 8, 358-366. https://doi.org/10.1016/j.jff.2014.04.001